Analysed BRIDGEBIO PHARMA INC (BBIO:NASDAQ) News Sources
$19.6B Infusion In US Plants With Lower Drug Prices: White House’s Deal With Mid-size Drugmakers
31-08-2026
stocktwits.com
Trump lines up MFN deals with nine mid-size pharmas on drug pricing push
01-09-2026
pharmaceutical-technology.com
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
02-09-2026
yahoo.com
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
26-08-2026
yahoo.com
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
31-08-2026
yahoo.com
BridgeBio (BBIO) Reported Signs of Cardiac Reversal With Acoramidis. How Much Weight Should Investors Give a Completer Analysis?
04-09-2026
yahoo.com
What is the current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The current price of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is $68.3.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) absolute price change since previous trading day?
The absolute price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is $-0.09.
BRIDGEBIO PHARMA INC (BBIO:NASDAQ) percentage price change since previous trading day?
The percentage price change of BRIDGEBIO PHARMA INC (BBIO:NASDAQ) since the previous trading day is -0.1316%.
What is the most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent average sentiment score for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is 52 out of 100.
What is the most recent average sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ)?
The most recent sentiment for BRIDGEBIO PHARMA INC (BBIO:NASDAQ) is .
SEC-8K** Filing Available For BRIDGEBIO PHARMA INC (BBIO:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.